
Overview
Dr. Alfred Chung is a hematologist-oncologist who cares for patients with blood cancers, including leukemias, lymphomas and myelomas. He sees patients who are in the hospital for treatment, including those who need a bone marrow transplant and those receiving chemotherapy or cellular therapies to bolster the immune system. Chung's research centers on the study and development of new therapies for plasma cell disorders, including multiple myeloma and amyloidosis (buildup of an abnormal protein called amyloid in the organs). One specific area of study is light chain amyloidosis, in which the dysfunction of certain antibody-producing cells results in abnormal protein fibers in the organs. Chung is looking specifically at targeted therapies to treat this type of amyloidosis as well as novel therapeutic strategies in the treatment of multiple myeloma. After earning a bachelor's degree in chemical engineering at the University of Michigan, Chung earned a medical degree at Northwestern University Feinberg School of Medicine. At Stanford Medicine, he completed a residency in internal medicine, followed by a fellowship in hematology and oncology. Chung is a member of the American Society of Clinical Oncology, American Society of Hematology and Association of Northern California Oncologists.
Dr. Chung is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Transplant, and Bone Marrow Aspiration.
Dr. Chung is board certified in American Board Of Internal Medicine/Hematology, Hematology, American Board Of Internal Medicine, Medical Oncology, and American Board Of Internal Medicine, Internal Medicine. He is actively involved in clinical research, co-authoring 29 peer reviewed articles and participating in 1 clinical trial. Dr. Chung is currently accepting new patients.
Graduate Institution
Residency
Specialties
Licenses
Board Certifications
Fellowships
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- MEDICARE MAPD
- MEDICARE SNP
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- MEDICARE SNP
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
Accepted plan types not found. Please verify directly with the provider.
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MEDICARE MAPD
- EPO
- HMO
- POS
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
400 Parnassus Ave., Fourth Floor, San Francisco, CA 94143
Additional Areas of Focus
Dr. Chung has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Cutaneous Lymphoma Clinic
Dr. Wei Ai is a blood cancer specialist who cares for adults with conditions such as Hodgkin's lymphoma and non-Hodgkin's lymphoma, including cutaneous lymphomas, which primarily involve the skin. She also sees patients needing blood and bone marrow transplantation. In her research, Ai focuses on novel approaches to lymphoma treatment, especially targeted agents for T-cell lymphomas. Her studies often lead to clinical trials of new therapies that target cancer at the molecular level. Ai earned a doctoral degree in microbiology and immunology as well as her medical degree from Stanford University School of Medicine. She completed a residency in internal medicine at UCSF, followed by fellowship training in medical oncology at Stanford. Dr. Ai is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), T-Cell Lymphoma, Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Ai is board certified in American Board Of Internal Med/Medical Oncology, Medical Oncology. Dr. Ai is currently accepting new patients.
Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program
Dr. James Rubenstein is a hematologist-oncologist, or a specialist in blood disorders. He has particular expertise in treating patients with neurologic complications from cancer, including patients with non-Hodgkin's lymphoma involving the brain (called central nervous system lymphoma). He also specializes in patients with cancer that has spread to the brain from other parts of the body. In his research, Rubenstein investigates immunologic tools to improve tumor response to chemotherapy and radiation treatment, and to minimize toxicity from treatment. He is also interested in developing tumor biomarkers to diagnose brain tumors. Rubenstein earned his medical degree at Weill Cornell Medicine and completed a residency in internal medicine at Stanford Medicine. He earned a doctorate in molecular and cellular neurosciences at the Rockefeller University. He completed a fellowship in hematology and oncology at UCSF, which included training in neuro-oncology. Rubenstein has won research awards from the Leukemia & Lymphoma Society and the National Cancer Institute. He is a member of the American Society of Hematology, American Society of Clinical Oncology and American Association for Cancer Research. Dr. Rubenstein is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Primary Lymphoma of the Brain, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Vitrectomy, and Bone Marrow Aspiration. Dr. Rubenstein is board certified in American Board Of Internal Med/Medical Oncology, Medical Oncology. Dr. Rubenstein is currently accepting new patients.
Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program
Dr. Jeffrey L. Wolf is a hematologist with expertise in cancers of the bone marrow and blood, as well as in bone marrow transplantation to treat these cancers. His primary focus in both patient care and research is myeloma, the second most common blood cancer. He directs UCSF's Multiple Myeloma Program and the Stephen and Nancy Grand Multiple Myeloma Translational Initiative – a program to support the development of better treatments – at the UCSF Helen Diller Family Comprehensive Cancer Center. Wolf's current research interests are in measuring minimal residual disease in patients who have undergone successful treatment for myeloma, as the results are useful in predicting long-term survival. Wolf earned his medical degree at the University of Illinois College of Medicine at Chicago and completed a residency in medicine at the University of California, San Diego. He completed a fellowship in hematology and oncology at UCSF, followed by a bone marrow transplantation rotation at the Fred Hutchinson Cancer Research Center. In 1979, Wolf helped establish the bone marrow transplant program at the City of Hope Comprehensive Cancer Center in Duarte, California. In 1984, he helped establish the first bone marrow transplant unit based at a community hospital in the United States, at Alta Bates Summit Medical Center in Berkeley. He joined UCSF in 2007. Dr. Wolf is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Wolf is board certified in American Board Of Internal Medicine/Hematology, Hematology and American Board Of Internal Medicine, Internal Medicine. Dr. Wolf is currently accepting new patients.
Frequently Asked Questions about Dr. Alfred Chung
How do I make an appointment with Dr. Alfred Chung?
You can book an appointment with Dr. Alfred Chung by calling their office at 415-353-2051. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Alfred Chung a top-rated expert for Multiple Myeloma?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Alfred Chung is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Alfred Chung specialize in?
While Dr. Alfred Chung is a Hematology Oncology, they have specific expertise in Multiple Myeloma, Smoldering Multiple Myeloma, and Monoclonal Gammopathy of Undetermined Significance (MGUS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.
Does Dr. Alfred Chung participate in research or clinical trials?
Yes. Dr. Alfred Chung has published 29 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Alfred Chung's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Alfred Chung accept my insurance?
Dr. Alfred Chung accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 415-353-2051 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Multiple MyelomaDr. Chung isElite. Learn about Multiple Myeloma.
- Distinguished
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Relapsed Refractory Multiple Myeloma (RRMM)
- Smoldering Multiple MyelomaDr. Chung isDistinguished. Learn about Smoldering Multiple Myeloma.
- Advanced
- Bone Marrow TransplantDr. Chung isAdvanced. Learn about Bone Marrow Transplant.
- Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
- GTP Cyclohydrolase 1 DeficiencyDr. Chung isAdvanced. Learn about GTP Cyclohydrolase 1 Deficiency.
- Primary AmyloidosisDr. Chung isAdvanced. Learn about Primary Amyloidosis.
- Pseudocholinesterase DeficiencyDr. Chung isAdvanced. Learn about Pseudocholinesterase Deficiency.
- Schnitzler SyndromeDr. Chung isAdvanced. Learn about Schnitzler Syndrome.
- Experienced
- Acute Lymphoblastic Leukemia (ALL)Dr. Chung isExperienced. Learn about Acute Lymphoblastic Leukemia (ALL).
- Acute Myeloblastic Leukemia with Maturation
- Acute Myeloblastic Leukemia without Maturation
- Acute Myeloid Leukemia (AML)Dr. Chung isExperienced. Learn about Acute Myeloid Leukemia (AML).
- AgranulocytosisDr. Chung isExperienced. Learn about Agranulocytosis.
- Aplastic AnemiaDr. Chung isExperienced. Learn about Aplastic Anemia.


